ERBB2 and breast carcinoma: This assay was recently used to demonstrate that normal or cancer‐associated fibroblasts (CAFs) from mammary and brain tissue induce resistance to the HER2 inhibitor, lapatinib, in HER2 overexpressing breast cancers (Marusyk et al, 2016).